MeiraGTx Holdings plc (MGTX) is a vertically-integrated global company committed to developing gene therapies to rectify inherited and age-related diseases. The company's headquarters are based in London and New York. MeiraGTx's wide-ranging array of novel technology includes a patented system for designing AAV vectors, a system of optimized self-complementary (sc) AAV vectors, and a technologically-advanced manufacturing process that promotes the streamlined production of gene therapy treatments.
This dedicated life science company focuses on three primary areas: ophthalmology, neurodegenerative diseases, and salivary gland hypofunction. It's actively developing gene therapies that directly address inherited retinal disorders (IRDs), dry age-related macular degeneration (AMD), xerostomia, and neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD).
MeiraGTx's promising gene therapy solutions embrace the power of genetic instructions to potentially undertake root cause rectifications with sustained effects. This strategy promises lasting resolutions with potentially fewer and less frequent treatments.
The firm's approach to designing novel AAV vectors has been patented and provides an excellent platform for generating gene therapy vectors with optimal properties for clinical applications. Additionally, the ability to create optimized self-complementary (sc) AAV vectors is a significant plus. These scAAV vectors expedite the production of the therapeutic protein after a gene therapy treatment, making them more effective and efficient.
Furthermore, MeiraGTx uses a proprietary, technologically advanced, and streamlined manufacturing process that complements its innovative gene therapy development process. This ensures consistency and quality in the production of these revolutionary therapies.
With a commitment to innovation and development, MeiraGTx continuously evaluates the pivotal dynamics within the field of gene therapy and follows scientific advances and insights that can steer their research trajectory.
The ultimate goal of MeiraGTx is to transform the lives of patients by exploring and formulating new gene therapy pathways to potentially cure diseases with significant unmet medical needs. It's a forward-thinking enterprise that is genuinely determined to bring transformative gene therapy solutions to patients all around the world.